AdAlta (ASX:1AD) Total Receivables: A$0.27 Mil (As of Dec. 2025)


What is AdAlta Total Receivables?

AdAlta ASX:1AD +33.33% Total Receivables is A$0.27 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

AdAlta's Total Receivables for the quarter that ended in Dec. 2025 was A$0.27 Mil.

AdAlta Total Receivables Historical Data

* Premium members only.

The historical data trend for AdAlta's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AdAlta Total Receivables Chart

AdAlta Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only 2.98 1.79 2.70 1.95 0.84

AdAlta Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.95 0.47 0.84 0.27

AdAlta Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$0.27 Mil mean?
AdAlta (ASX:1AD) has a Total Receivables of A$0.27 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on AdAlta and its competitors.
Is AdAlta's Total Receivables too high?
AdAlta's current Total Receivables is A$0.27 Mil.
How does AdAlta's Total Receivables compare to VRTX and REGN?
AdAlta's Total Receivables of A$0.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on AdAlta and its competitors. AdAlta's current Total Receivables is A$0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AdAlta stock overvalued right now?
AdAlta (ASX:1AD) has a current Total Receivables of A$0.27 Mil. The current Total Receivables is A$0.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For AdAlta (ASX:1AD), the current Total Receivables is A$0.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AdAlta Business Description

Address 697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation cells and protein based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.